LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 3 | B15 | 72 | hr | 1401 | 1420 | 4545 | 0.3124 | 0.0077 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 1 | B14 | 72 | hr | 1401 | 1420 | 3978 | 0.3569 | 0.0087 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 2 | B14 | 72 | hr | 1401 | 1463 | 4213 | 0.3472 | 0.0274 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 3 | B14 | 72 | hr | 1401 | 1403 | 4545 | 0.3086 | 0.0006 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 1 | B13 | 72 | hr | 1401 | 1503 | 3978 | 0.3778 | 0.0475 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 2 | B13 | 72 | hr | 1401 | 1644 | 4213 | 0.3902 | 0.1057 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 3 | B13 | 72 | hr | 1401 | 1541 | 4545 | 0.3390 | 0.0575 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 1 | N18 | 72 | hr | 1401 | 4420 | 4139 | 1.0679 | 1.0859 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 2 | N18 | 72 | hr | 1401 | 4134 | 4095 | 1.0094 | 1.0122 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 3 | N18 | 72 | hr | 1401 | 4700 | 4272 | 1.1001 | 1.1222 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 1 | N17 | 72 | hr | 1401 | 4416 | 4139 | 1.0669 | 1.0847 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 2 | N17 | 72 | hr | 1401 | 4515 | 4095 | 1.1025 | 1.1302 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 3 | N17 | 72 | hr | 1401 | 4746 | 4272 | 1.1109 | 1.1351 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 1 | N16 | 72 | hr | 1401 | 4823 | 4139 | 1.1653 | 1.2057 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 2 | N16 | 72 | hr | 1401 | 4287 | 4095 | 1.0468 | 1.0600 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 3 | N16 | 72 | hr | 1401 | 4387 | 4272 | 1.0268 | 1.0332 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 1 | N15 | 72 | hr | 1401 | 4619 | 4139 | 1.1160 | 1.1455 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 2 | N15 | 72 | hr | 1401 | 4582 | 4095 | 1.1188 | 1.1506 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 3 | N15 | 72 | hr | 1401 | 4543 | 4272 | 1.0633 | 1.0779 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 1 | N14 | 72 | hr | 1401 | 4458 | 4139 | 1.0771 | 1.0973 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 2 | N14 | 72 | hr | 1401 | 4431 | 4095 | 1.0820 | 1.1045 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 3 | N14 | 72 | hr | 1401 | 4489 | 4272 | 1.0507 | 1.0625 |
| SK-BR-3 | Imatinib | 10 | uM | LJP6 | 1 | N13 | 72 | hr | 1401 | 4120 | 4139 | 0.9954 | 0.9941 |
| SK-BR-3 | Imatinib | 10 | uM | LJP6 | 2 | N13 | 72 | hr | 1401 | 4159 | 4095 | 1.0155 | 1.0200 |
| SK-BR-3 | Imatinib | 10 | uM | LJP6 | 3 | N13 | 72 | hr | 1401 | 4495 | 4272 | 1.0521 | 1.0642 |